• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi mourns passing of Guy Mazué

Respected toxicologist was a long-time colleague and friend to DNDi

21 Feb 2020

DNDi has learned, with great sadness, that long-time colleague and friend Guy Mazué has passed away. Guy worked closely with DNDi from its founding in 2003 and even before, advising the working group that created DNDi. He was involved in much of the organization’s toxicology work for many years, including on pre-clinical and clinical drug candidates for malaria, sleeping sickness, and leishmaniasis.

“He was a wise person, larger than life, and a friend and mentor to several of us within the DNDi team,” said Dr Bernard Pécoul, Executive Director, DNDi. “Guy worked with us as a consultant from the beginning; it was a privilege to count on his collaboration and expertise.”

“For me, he was like a mentor, a guide. I learned a lot with him,” said Stéphanie Braillard, Non-Clinical Development Senior Manager, DNDi. “He was very generous, and especially generous with the help he provided. If I had any questions regarding a molecule, a safety concern, a strategy to move ahead, I could ask him at any time.”

As an expert toxicologist, Guy worked in senior posts at Sanofi and, later, Pharmacia and Upjohn, where he was Vice President, Deputy Worldwide Toxicology. He was also an expert and member of several working groups of the French drug regulatory agency, Agence Nationale de Sécurité du Médicament et des Produits de Santé.

“He had a lot of patience to share, explain, and teach, and he had a great sense of humour and a lot of humility,” noted Dr Robert Don, Discovery & Pre-Clinical Director at DNDi from 2005 to 2017. “The whole drug discovery group would turn to Guy for explanations. He really taught people toxicology.”

After his retirement, Guy continued to work as a consultant, including with DNDi, most recently helping the team to successfully bring leishmaniasis drug candidates DNDI-0690 and DNDI-6148 to first-in-human clinical trials. Even after he stopped working as a consultant, he continued to answer questions from the Discovery and Translation teams.

Guy was also a keen winemaker and connoisseur, a great cook, and an organizer of wonderful parties.

“He had a great laugh, and also these big workers’ hands, not the hands you might expect of someone who worked in offices and labs! Big calloused hands from working outside in the field. He produced wine from his own grapes,” remembered Dr Isabela Ribeiro, Head, Dynamic Portfolio Unit, DNDi, who first met Guy in the 1990s when they both worked at Pharmacia.

“When I retired from DNDi, his farewell gift to me was a lovely bottle of his own eau de vie,” said Robert.

“I will definitely think of Guy when I finish my own bottles of Mirabelle and Poire William. This might take a few years!” added Stéphanie.

Guy would have celebrated his 76th birthday last week.

Read, watch, share

Loading...
Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License